Search clinical trials for: ODM-201

Total 4685 results

Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Renal Impairment

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Hepatic Impairment

United States
MedRegen LLC

Recruiting

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

Wound of Skin | Abdominal Wound

United States
Anbogen Therapeutics, Inc.

Recruiting

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Non Small Cell Lung Cancer | Advanced Solid Tumor | HER2 Mutations

Taiwan
Dyne Therapeutics

Recruiting

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 (ACHIEVE)

Myotonic Dystrophy Type 1 (DM1)

United Kingdom, France, Netherlands, Italy, Germany, New Zealand
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation

Recruiting

A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa (CoTeT)

COVID-19

South Africa
MedRegen LLC
Johns Hopkins University; ICON plc

Recruiting

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

COVID-19 | ARDS, Human | Regeneration | Stem Cells

United States
ICM Co. Ltd.

Enrolling by invitation

A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo

Osteoarthritis, Knee

Australia
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrui Biotechnology Co. Ltd

Terminated

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

COVID-19

China
GenSpera, Inc.
Food and Drug Administration (FDA)

Completed

Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme

United States
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia Acute Myeloid

France
Kanyos Bio, Inc., a wholly-owned subsidiary of...

Completed

Assessment of KAN-101 in Celiac Disease (ACeD)

Celiac Disease

United States
Nacuity Pharmaceuticals, Inc.
Foundation Fighting Blindness

Active, not recruiting

Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (SLO RP)

Usher Syndromes

Australia
ILIAS Biologics Inc.

Completed

A Study to Evaluate the Safety and Tolerability of ILB-202

Healthy

Australia
Alumis Inc

Completed

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Plaque Psoriasis

United States, Canada, Czechia
Anebulo Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test

Acute Cannabinoid Intoxication

Netherlands
Xeno Biosciences

Completed

A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101

Healthy

Hungary
Bright Minds Biosciences Pty Ltd

Completed

A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers

Healthy

Australia
Bloom Science

Completed

A Phase Ia Safety and Tolerability Study of BL-001

Healthy Volunteers

Switzerland
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Netherlands, United Kingdom, Czechia, Portugal, Hungary
Ossium Health, Inc.

Withdrawn

Mesenchymal Stem Cells (MSCs) for Perianal Fistula

Rectal Fistula
Novartis Gene Therapies

Completed

Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1

Spinal Muscular Atrophy 1

United States
Cure Rare Disease, Inc
University of Massachusetts, Worcester

Active, not recruiting

Treatment of a Single Patient With CRD-TMH-001

Duchenne Muscular Dystrophy

United States
Teres Bio, Inc.

Completed

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
ImmunityBio, Inc.

Completed

Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Scar Prevention

United States
Novo Nordisk A/S

Completed

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

Anemia

United States
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Czechia, Portugal, Hungary, Germany, Poland
Medasense Biometrics Ltd

Terminated

Performance Assessment Of The PMD-200 In Subjects With Degenerative Lumbar Spine Disease Who Requires Surgical Procedure

Degenerative Diseases, Nervous System

Israel
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis

Bacterial Enteritis

Korea, Republic of, Singapore, Japan
Tongji Hospital

Unknown

Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health. (COVID-19)

Coronavirus Disease 2019

China
Taiho Pharmaceutical Co., Ltd.

Completed

A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Japan
Olympus Corporation

Terminated

A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema

Emphysema

Japan
Dynavax Technologies Corporation

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Healthy

United States
Derming SRL

Completed

Efficacy and Tolerance Evaluation of an Injective Treatment for the Area Around the Eyes

Under-eyes Dark Circles

Italy
Corindus Inc.

Completed

Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease (RAPID)

Peripheral Arterial Disease

Austria
X4 Pharmaceuticals
Covance

Terminated

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Healthy

United States
Auris Medical, Inc.

Completed

AM-101 in the Treatment of Acute Tinnitus 2 (TACTT2)

Tinnitus

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects

Bacterial Enteritis

United Kingdom
Arava Bio Tech Ltd.
Cato Research

Unknown

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

Wounds and Injuries

United States
Akron Molecules AG

Completed

A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain

Osteoarthritis

Austria
Xenon Pharmaceuticals Inc.

Completed

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Inherited Erythromelalgia | Primary Erythromelalgia

Netherlands
MediciNova

Completed

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

Asthma

United States
Vicept Therapeutics, Inc.
Accenture

Completed

Dose Response Study of Patients With Erythematous Rosacea

Erythematous (Type One) Rosacea

United States
University of Southern California
National Cancer Institute (NCI); Sanofi

Terminated

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Diarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Eleusis Therapeutics
Beckley Psytech Pty Ltd

Recruiting

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

Depression | Healthy Volunteers | Major Depressive Disorder

United Kingdom
Novartis Pharmaceuticals

Recruiting

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Non-Small Cell Lung Carcinoma

India
Kythera Biopharmaceuticals

Completed

A Study to Assess Injection Comfort of Two Formulations of ATX-101

Healthy

United States
Sunovion Respiratory Development Inc.

Completed

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (GOLDEN 6)

COPD

United States
Scioderm, Inc.
Amicus Therapeutics

Completed

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

Italy, Spain, Serbia, United States, Australia, Netherlands, Austria, Germany, Israel, Lithuania, France, United Kingdom, Poland

Search clinical trials for: ODM-201

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations